]>
IRCT20160717028967N8 IRCT 2018-06-30 Kermanshah University of Medical Sciences Compareing effects of venlafaxine and Placebo on depression, withdrawal symptoms, craving The efficacy of venlafaxine in the treatment of depression, withdrawal symptoms, craving for methamphetamine compared with placebo (clinical trial with a control group) 2018-07-21 anticipated 66 Complete https://irct.ir/trial/31718 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization, Blinding description: The medication and placebo are delivered to the patient without sticking the label. The doctor is also unaware of the type of drug used in each group. The color and smell of main drug and placebo are the same. 2 Addiction. Intervention 1: Intervention group: The group will receive duloxetine treatment in two months. Intervention 2: Control group: The control group will receive placebo treatment in two months. Yes - There is a plan to make this available What will be shared: I have no plans at this time When: I have no plans at this time To whom: I have no plans at this time Conditions: I have no plans at this time Where to obtain: I have no plans at this time How to obtain: I have no plans at this time Comments:
public Faezeh Tatari
Farabi Hospital, Isar square
Kermanshah Iran (Islamic Republic of) 6719851115 +98 83 3826 4513 tatari@yahoo.com Kermanshah University of Medical Sciences scientific Faezeh Tatari
Farabi Hospital, Isar square
Kermanshah Iran (Islamic Republic of) 6719851115 +98 833826513 s_salemi85@yahoo.com Kermanshah University of Medical Sciences Iran (Islamic Republic of) Gender Male Methamphetamine dependence diagnoses accordingly Diagnostic and Statistical Manual of Mental Disorders fifth edition The dominant use of methamphetamine for at least 6 months lack of serious psychiatric disorders no limit no limit Male Gender female No use of other drugs and stimulants at the time of entering the study The absence of comorbid psychiatric disorders symptoms F15 Mental and behavioral disorders due to use of other stimulants, including caffeine: dependence syndromes Treatment - Drugs Placebo Intervention group: The group will receive duloxetine treatment in two months Control group: The control group will receive placebo treatment in two months Depression. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Depression Inventory. Withdrawal symptoms. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Inventory withdrawal symptoms. Craving. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Craving Questionnaire. Kermanshah University of Medical Sciences Approved 2018-01-31 Ethics committee of Kermanshah University of Medical Sciences Building No.2, Shahid Beheshti Blvd, Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences Kermanshah Kermanshah Iran (Islamic Republic of)